2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2459

Personal and Environmental Factors Associated with Leisure Participation Among Children and Adolescents with Juvenile Idiopathic Arthritis
Abstract Number: 99

Personalised Genetic Medicine: HLA-DRB1 Amino Acid Positions 11, 71 and 74 Predict Inflammation Level, Disease Activity and Disability in Rheumatoid Arthritis
Abstract Number: 490

Personalizing the Treat to Target Approach in Rheumatoid Arthritis
Abstract Number: 1822

Pharmacokinetics of the Selective B-Cell Lymphoma-2 (Bcl-2) Inhibitor, ABT-199, in Female Subjects with Systemic Lupus Erythromatosus
Abstract Number: 2416

Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Six to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Abstract Number: 1918

Pharmacologic Targeting of Mitochondrial Dysfunction in Systemic Sclerosis: Enhanced SIRT3 Signaling
Abstract Number: 2873

Pharmacological Treatment of Psoriatic Arthritis (PSA): Systematic Literature Review for the Update of the EULAR Recommendations for the Management of PSA
Abstract Number: 319

Phase 1 Studies of Anti-Interleukin-1 Dual-Variable Domain Immunoglobulin in Healthy Subjects and Patients with Osteoarthritis
Abstract Number: 1217

Phenome-Wide Association Study of Novel Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis
Abstract Number: 2697

Phenome-Wide Association Study of Rheumatoid Arthritis Subgroups Identifies Association Between Seronegative Disease and Fibromyalgia
Abstract Number: 1471

Phenotypic Differences Between HLA-B27 Positive and Negative Children with Enthesitis-Related Arthritis
Abstract Number: 210

Phenotypically Divergences of Monocyte Subsets and Microparticles in Systemic Lupus Erythematosus Patients
Abstract Number: 1053

Phosphatidylinositol-3-Kinase Delta Pathway a Novel Therapeutic Target for Sjogren’s Syndrome
Abstract Number: 1103

Phosphatidylserine Outer Layer Translocation Is Implicated in IL-10 Secretion By Human Regulatory B Cells
Abstract Number: 2900

Phospholipase A2 Receptor 1 Antibody in Membranous Lupus Nephritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].